SCHEMBL4132540

SCHEMBL4132540

O=C(O)Cc1ccc(NC2=NC(=O)C(=CCc3cc4ccccc4o3)S2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.41
PDE4D Q08499 2/20 0.41
PSMB5 P28074 2/20 0.38
PSMB8 P28062 1/20 0.38
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
PLEC Q15149 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
IKBKB O14920 1/20 0.37
GLS O94925 2/20 0.37
NR1H4 Q96RI1 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CSNK2A1 P68400 2/20 0.35
P2RY14 Q15391 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634791 0.80 FFAR1 (0.47) PDE4BPDE4DNR1H4LMNA
SCHEMBL4132544 0.77 PDE4B (0.42) PDE4BPDE4DMEN1MAPTKMT2A
SCHEMBL4132534 0.77 PDE4B (0.42) PDE4BPDE4DMEN1MAPTKMT2A
SCHEMBL4140267 0.75 ALOX5 (0.47) PDE4BPDE4DMEN1KMT2AIKBKB
SCHEMBL4140263 0.75 ALOX5 (0.47) PDE4BPDE4DMEN1KMT2AIKBKB
SCHEMBL4133862 0.75 DUSP22 (0.49) PDE4BPOLBALDH1A1
SCHEMBL4133860 0.75 DUSP22 (0.49) PDE4BPOLBALDH1A1
SCHEMBL4137321 0.75 NR1H4 (0.41) PDE4BPDE4DMEN1MAPTKMT2A
SCHEMBL4137317 0.75 NR1H4 (0.41) PDE4BPDE4DMEN1MAPTKMT2A
SCHEMBL4635128 0.74 POLB (0.42) PDE4BPDE4DMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PDE4B 161/4885PDE4D 485/4885PSMB5 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.